Lung cancer accounts for 23% of all cancer-related deaths in American adults. Though several monoclonal antibody (mAb) treatments utilizing parenteral delivery have been commercialized, local delivery has been impossible. Recent advances in spray-drying technology show promising results and potentially facilitate more effective mAbs through direct delivery to the lung.
Local delivery of biotherapeutics to the lung holds great promise for the treatment of lung diseases, but development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge.
Spray drying is particularly advantageous for manufacturing particles in the inhalable range of 1-5 microns. Learn more about spray drying through two case studies of inhaled dry powders.
Kimberly Shepard, Ph.D., principal engineer, answers questions about how spray drying can address many challenges associated with late-stage lung cancer treatments.
This website uses cookies to ensure you get the best experience on our website. Learn more
